A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography
Maurizio Infante,Silvio Cavuto,Fabio Romano Lutman,Eliseo Passera,Maurizio Chiarenza,G Chiesa,Giorgio Brambilla,Enzo Angeli,Giuseppe Aranzulla,Arturo Chiti,Marta Scorsetti,Pierina Navarria,Raffaele Cavina,Michele Ciccarelli,Massimo Roncalli,Anna Destro,Edoardo Bottoni,Emanuele Voulaz,Valentina Errico,Giorgio Maria Ferraroli,Giovanna Finocchiaro,Luca Toschi,Armando Santoro,Marco Alloisio +23 more
TL;DR: The results of the DANTE (Detection and screening of early lung cancer with Novel imaging TEchnology) trial do not allow us to make a definitive statement about the efficacy of LDCT screening, but underline the importance of obtaining additional data from randomized trials with intervention-free reference arms before the implementation of population screening.
Journal ArticleDOI
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
Melina Verso,Giancarlo Agnelli,Sergio Bertoglio,Franco C. Di Somma,Francesco Paoletti,Walter Ageno,Mario Bazzan,P. Parise,Roberto Quintavalla,Emanuele Naglieri,Armando Santoro,Davide Imberti,Mariella Soraru,Stefano Mosca +13 more
TL;DR: No difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo, and the dose of enoxAParin used in this study proved to be safe.
Journal ArticleDOI
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
Federico Cappuzzo,Pasi A. Jänne,Margaret Skokan,Giovanna Finocchiaro,Elisa Rossi,C. Ligorio,Paolo Andrea Zucali,Luigi Terracciano,Luca Toschi,Massimo Roncalli,Annarita Destro,Matteo Incarbone,Marco Alloisio,Armando Santoro,Marileila Varella-Garcia +14 more
TL;DR: In this article, the MET gene copy number was analyzed using FISH in two related non-small-cell lung cancer cell lines, one sensitive (HCC827) and one resistant to gefitinib therapy and in two different NSCLC patient populations.
Journal ArticleDOI
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Martin Dreyling,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A. Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Muhit Ozcan,Marina Kosinova,Krimo Bouabdallah,Franck Morschhauser,Don A. Stevens,David Trevarthen,Marius Giurescu,Lisa Cupit,Li Liu,Karl Köchert,Henrik Seidel,Carol Peña,Shuxin Yin,Florian Hiemeyer,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +26 more
TL;DR: High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes, and this phase II study demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.
Journal ArticleDOI
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
Federico Cappuzzo,Gaetano Finocchiaro,Elisa Rossi,Pasi A. Jänne,C. Carnaghi,Cesare Calandri,Katia Bencardino,C. Ligorio,Fortunato Ciardiello,Tiziana Pressiani,Annarita Destro,Massimo Roncalli,L. Crinò,Wilbur A. Franklin,Armando Santoro,M. Varella-Garcia +15 more
TL;DR: CRC patients with high EGFR gene copy number have an increased likelihood to respond to cetuximab therapy, and Prospective clinical trials with a careful standardization of assay conditions and pattern interpretation are urgently needed.